Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay

Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay

Context Tucatinib (CYP2C8 substrate) and quercetin (CYP2C8 inhibitor) are two common drugs for the treatment of cancer. However, the effect of quercetin on the metabolism of tucatinib remains unknown.Objective We validated a sensitive method to quantify tucatinib levels in rat plasma based on ultra-...

Full description

Bibliographic Details
Main Authors:	Ying Zhang, Ya-nan Liu, Saili Xie, Xuegu Xu, Ren-ai Xu
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Series:	Pharmaceutical Biology
Subjects:	Drug–drug interaction cancer treatment HER2-positive breast cancer
Online Access:	https://www.tandfonline.com/doi/10.1080/13880209.2022.2048862

Similar Items

Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS
by: Shuanghu Wang, et al.
Published: (2023-05-01)

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
by: Zaid Sirhan, et al.
Published: (2022-07-01)

Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC‐MS/MS
by: Mengming Xia, et al.
Published: (2023-11-01)

Simultaneous determination of amiodarone, dronedarone, and their principal metabolites in SD rat plasma by UPLC-MS/MS and its application in pharmacokinetics
by: Ying Zhang, et al.
Published: (2021-08-01)

UPLC-MS/MS Measurement of the Effect of Isavuconazole, Itraconazole and Fluconazole on the Pharmacokinetics of Selinexor in Rats
by: Li S, et al.
Published: (2020-09-01)

Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats
by: Xueru He, et al.
Published: (2022-09-01)

In vivo Pharmacokinetic Drug-Drug Interaction Studies Between Fedratinib and Antifungal Agents Based on a Newly Developed and Validated UPLC/MS-MS Method
by: Congrong Tang, et al.
Published: (2021-02-01)

Pharmacokinetics of Herb-Drug Interactions of Plumbagin and Tazemetostat in Rats by UPLC-MS/MS
by: Li H, et al.
Published: (2022-09-01)

Establishment and validation of a UPLC-MS/MS bioassay for the quantification of infigratinib in rat plasma
by: Xuegu Xu, et al.
Published: (2022-07-01)

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives
by: Qiuji Wu, et al.
Published: (2020-08-01)

Inhibitory Mechanisms of Lekethromycin in Dog Liver Cytochrome P450 Enzymes Based on UPLC-MS/MS Cocktail Method
by: Pan Sun, et al.
Published: (2023-10-01)

A Drug–Drug Interaction Study to Evaluate the Impact of Simvastatin and Itraconazole on Erlotinib Pharmacokinetics in Rats by UPLC-MS/MS
by: Fan Z, et al.
Published: (2023-10-01)

UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma
by: Qingqing Li, et al.
Published: (2022-06-01)

A Simple UPLC/MS-MS Method for Simultaneous Determination of Lenvatinib and Telmisartan in Rat Plasma, and Its Application to Pharmacokinetic Drug-Drug Interaction Study
by: Yanjun Cui, et al.
Published: (2022-02-01)

Development and Validation of an Ecofriendly, Rapid, Simple and Sensitive UPLC-MS/MS Method for Entrectinib Quantification in Plasma for Therapeutic Drug Monitoring
by: Essam A. Ali, et al.
Published: (2023-09-01)

Analytical methodology and pharmacokinetic study of elagolix in plasma of rats using a newly developed UPLC-MS/MS assay
by: Qiong Wang, et al.
Published: (2021-07-01)

Development of a UPLC-MS/MS method for the determination of orelabrutinib in rat plasma and its application in pharmacokinetics
by: Ya-nan Liu, et al.
Published: (2022-09-01)

Eco-Friendly UPLC-MS/MS Quantitation of Delafloxacin in Plasma and Its Application in a Pharmacokinetic Study in Rats
by: Muzaffar Iqbal, et al.
Published: (2021-09-01)

Development and validation of the quantitative determination of avapritinib in rat plasma by a bioanalytical method of UPLC-MS/MS
by: Xuegu Xu, et al.
Published: (2021-06-01)

Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine
by: Mohamed Abouzid, et al.
Published: (2024-01-01)

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
by: Peter A. Kaufman, et al.
Published: (2023-10-01)

Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer
by: Minghui Yu, et al.
Published: (2023-03-01)

HER2-positive breast cancer – Available anti-HER2 therapies and new agents under investigation
by: Martyna Zielińska, et al.
Published: (2020-06-01)

Effect of Baicalein on the Pharmacokinetics of Cilostazol and Its Two Metabolites in Rat Plasma Using UPLC-MS/MS Method
by: Qinghua Weng, et al.
Published: (2022-04-01)

Determination of 30 Kinds of Antiparasitic Drugs in Animal-derived Foods by QuEChERS-UPLC-MS/MS
by: Lifeng FENG, et al.
Published: (2024-03-01)

Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo
by: Ya-nan Liu, et al.
Published: (2023-05-01)

A high throughput method for Monitoring of Sorafenib, regorafenib, cabozantinib and their metabolites with UPLC-MS/MS in rat plasma
by: Er-Min Gu, et al.
Published: (2022-09-01)

2‐Deoxyglucose and hydroxychloroquine HPLC‐MS–MS analytical methods and pharmacokinetic interactions after oral co‐administration in male rats
by: Dongxiao Sun, et al.
Published: (2024-02-01)

Comparative Pharmacokinetics of Cinobufacini Capsule and Injection by UPLC-MS/MS
by: Ming Li, et al.
Published: (2022-07-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-05-01)

UPLC-MS/MS quantification of quercetin in plasma and urine following parenteral administration
by: Igor A. Zupanets, et al.
Published: (2019-01-01)

Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS
by: Ying Li, et al.
Published: (2022-07-01)

miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review
by: Thanh Hoa Vo, et al.
Published: (2024-03-01)

MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast Cancer
by: Weiru Chi, et al.
Published: (2023-12-01)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
by: Yu Y, et al.
Published: (2022-12-01)

A Reliable and Effective UPLC-MS/MS Method for the Determination of Oprozomib in Rat Plasma
by: Xia Li, et al.
Published: (2023-01-01)

UPLC–MS/MS assay for quantification of an inhibitor of kinases (Foretinib) in plasma: Application to a pharmacokinetic study in rats
by: Essam Ezzeldin, et al.
Published: (2020-04-01)

Characterization of Alpelisib in Rat Plasma by a Newly Developed UPLC-MS/MS Method: Application to a Drug-Drug Interaction Study
by: Qiong Wang, et al.
Published: (2021-11-01)

The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions
by: Saleh Alrhmoun, et al.
Published: (2022-12-01)

Effects of <i>Catha edulis</i> (Khat) on the Pharmacokinetics of Metformin in Diabetic Rats Using UPLC/MS/MS Analysis and Its Impact on Hepatic CYP450 Enzymes
by: Ali S. Alqahtani, et al.
Published: (2023-08-01)